A Phase III, open, randomized, multicenter, comparative vaccination study to evaluate the immunogenicity and reactogenicity of various formulations of a monovalent candidate pandemic influenza A vaccine in individuals over 60 years of age
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Influenza A virus vaccine-H9N2 (Primary)
- Indications Influenza A virus H9N2 subtype
- Focus Pharmacodynamics
- 10 Feb 2020 Biomarkers information updated
- 12 Oct 2008 Study phase changed from III to II as reported by ClinicalTrials.gov.
- 02 Feb 2007 Status changed from in progress to completed.